Share This Page
Details for Patent: 6,488,027
✉ Email this page to a colleague
Summary for Patent: 6,488,027
| Title: | Powder inhaler | ||||||||||||||||||||||||||||||||||||
| Abstract: | This invention relates to single dose dry powder inhalers in which medicament is stored in a capsule and is released by piercing the capsule wall with polymer-coated steel pins. Methods of preparation of polymer-coated piercing means and their use in releasing the medicament from the capsule are described. | ||||||||||||||||||||||||||||||||||||
| Inventor(s): | Claude Moulin | ||||||||||||||||||||||||||||||||||||
| Assignee: | Novartis AG | ||||||||||||||||||||||||||||||||||||
| Application Number: | US09/657,967 | ||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Delivery; Device; Dosage form; | ||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | Scope, Claims, and US Patent Landscape for US Patent 6,488,027US Patent 6,488,027 covers an inhaler device with a steel capsule-piercing element that is surface-engineered with a two-part coating system. The coating is designed so the piercing element both pierces a capsule and resists degradation at the capsule interface, using (1) a metal-alloy “alloy layer” and (2) an “alloy matrix layer” that disperses inert polymer particles in a metal-alloy matrix. What is protected in US 6,488,027?What is the core claimed structure?Claim 1 defines an inhaler device comprising:
This is the claim’s essential combination: steel piercing element + two-layer coating architecture + specific metals + dispersed inert polymer particles. What elements narrow claim scope beyond claim 1?Claims 2 to 11 narrow by specifying the metal set, the polymer family, the inclusion of phosphorus, the alloy composition ranges, the PTFE selection, and coating thickness/volume fraction. Claim-by-claim scope map (from the text provided)
What metals and polymer families fall inside the claim set?What metals qualify for the alloy layer and the alloy matrix layer?Claim 1 uses three metal buckets: chromium, Group VIII metal, noble metal. Claim 2 explicitly enumerates a narrower set for “the metal,” listing:
Claim 3 selects nickel. Claim 4 adds phosphorus to the alloy matrix. Claim 9 specifies both coating layers using nickel-phosphorus chemistry plus PTFE particles in the matrix. In practice, the protected chemistries collapse to nickel-phosphorus alloy with PTFE dispersion when the narrower dependent claims are invoked (claims 3, 5, 6, 8, 9, 11, with thickness limits in claim 10). What polymers qualify?
How strong is the claim architecture for enforcement?What gives the patent a distinct scope advantage?The combination is specific in three independent dimensions: 1) Device interface element: the steel capsule-piercing means that contacts and pierces the capsule That structure helps distinguish from:
Which claims create “high-confidence” infringement zones?The dependent claims create the tightest, most easily measurable infringement boundaries:
These parameters are testable in forensic claim construction and technical diligence. Claim scope outcomes: what design-arounds likely sit outside?What substitutions likely avoid claim 1 while staying “close”?Claim 1 is broad on metal buckets and polymer category, but it is strict on architecture: a two-layer coating with an alloy layer and an alloy matrix layer where polymer particles are dispersed in an alloy matrix. Potential outside-the-claim approaches (conceptual, based on the claim language you provided):
What substitutions likely avoid claims 2-11 specifically?To avoid the narrower dependents:
Landscape analysis: where does this sit in the broader inhaler surface-coating field?What is the likely “technical neighborhood” of US 6,488,027?Even without the specification text or citation list, the claims point to a narrow niche:
In the patent landscape, this is typically adjacent to:
What does the claim set imply about novelty strategy?The claim structure suggests the “novelty” sits in combining:
That combination is the enforceable hook. A buyer or licensee evaluates freedom-to-operate around whether the piercing interface is steel and whether it uses the defined two-layer composite coating architecture. Practical enforcement and diligence checklist (based on claim language)What technical facts must be verified in an accused product?For claim 1 (and especially for claims 7-11), diligence should establish:
What measurement methods map to the claims?
Key takeaways
FAQsDoes claim 1 require PTFE specifically?No. Claim 1 requires “inert polymer particles” in an alloy matrix layer, and PTFE is only required by dependent claims 7-9 and 11. Is phosphorus required for claim 1?No. Phosphorus is added in claim 4 and subsequent dependent claims; claim 1 does not require phosphorus. What is the narrowest independent boundary in the provided claim set?Claim 9 plus claim 10 plus claim 11 create the tightest implementation: Ni-P alloy in the alloy layer, Ni-P alloy matrix with PTFE particles, defined layer thicknesses, and PTFE volume fraction 20-30%. How strict are the composition and thickness windows?They are explicit ranges:
Can a device infringe even if only part of the piercing element is coated?Claim 1 requires “at least a portion” of the capsule-piercing means that contacts and pierces the capsule be coated with the two-layer system. References
More… ↓ |
Drugs Protected by US Patent 6,488,027
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,488,027
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 9805102 | Mar 10, 1998 |
International Family Members for US Patent 6,488,027
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 283083 | ⤷ Start Trial | |||
| Australia | 3032399 | ⤷ Start Trial | |||
| Australia | 750844 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
